{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:58:32Z","timestamp":1787313512670,"version":"build-2736575974"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10072-023-07258-x","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T21:02:21Z","timestamp":1703192541000},"page":"2471-2487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Is blood pTau a reliable indicator of the CSF status? A narrative review"],"prefix":"10.1007","volume":"45","author":[{"given":"Annibale","family":"Antonioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela Maria","family":"Raho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9871-229X","authenticated-orcid":false,"given":"Francesco","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"issue":"10284","key":"7258_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, Cummings J, van der Flier WM (2021) Alzheimer\u2019s disease. Lancet (London, England) 397(10284):1577\u20131590. https:\/\/doi.org\/10.1016\/S0140-6736(20)32205-4","journal-title":"Lancet (London, England)"},{"issue":"1","key":"7258_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12929-019-0524-y","volume":"26","author":"MVF Silva","year":"2019","unstructured":"Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MDG (2019) Alzheimer\u2019s disease: risk factors and potentially protective measures. J Biomed Sci 26(1):33. https:\/\/doi.org\/10.1186\/s12929-019-0524-y","journal-title":"J Biomed Sci"},{"issue":"6","key":"7258_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med 284(6):643\u2013663. https:\/\/doi.org\/10.1111\/joim.12816","journal-title":"J Intern Med"},{"issue":"1","key":"7258_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13311-021-01146-y","volume":"19","author":"JA Trejo-Lopez","year":"2022","unstructured":"Trejo-Lopez JA, Yachnis AT, Prokop S (2022) Neuropathology of Alzheimer\u2019s disease. Neurotherapeutics 19(1):173\u2013185. https:\/\/doi.org\/10.1007\/s13311-021-01146-y","journal-title":"Neurotherapeutics"},{"issue":"6","key":"7258_CR5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH (2021) Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. The Lancet Neurology 20(6):484\u2013496. https:\/\/doi.org\/10.1016\/S1474-4422(21)00066-1","journal-title":"The Lancet Neurology"},{"issue":"4","key":"7258_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Contributors (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s & dementia 14(4):535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimer\u2019s & dementia"},{"issue":"18","key":"7258_CR7","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1002\/hbm.24782","volume":"40","author":"A Chandra","year":"2019","unstructured":"Chandra A, Valkimadi PE, Pagano G, Cousins O, Dervenoulas G, Politis M, Alzheimer\u2019s Disease Neuroimaging Initiative (2019) Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer\u2019s disease and mild cognitive impairment. Hum Brain Mapp 40(18):5424\u20135442. https:\/\/doi.org\/10.1002\/hbm.24782","journal-title":"Hum Brain Mapp"},{"issue":"7","key":"7258_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, H\u00f6ltt\u00e4 M, Ros\u00e9n C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H (2016) CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. The Lancet Neurology 15(7):673\u2013684. https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3","journal-title":"The Lancet Neurology"},{"issue":"3","key":"7258_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, Blennow K, Reiman EM, Stomrud E, Dage JL, Hansson O (2020) Plasma PTau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26(3):379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1","journal-title":"Nat Med"},{"issue":"1","key":"7258_CR10","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O (2022) Blood-based biomarkers for Alzheimer\u2019s disease. Embo molecular medicine 14(1):e14408. https:\/\/doi.org\/10.15252\/emmm.202114408","journal-title":"Embo molecular medicine"},{"issue":"15","key":"7258_CR11","doi-asserted-by":"publisher","first-page":"12151","DOI":"10.3390\/ijms241512151","volume":"24","author":"S Toniolo","year":"2023","unstructured":"Toniolo S, Di Lorenzo F, Bernardini S, Mercuri NB, Sancesario GM (2023) Blood-brain barrier dysfunction and A\u03b242\/40 ratio dose-dependent modulation with the ApoE genotype within the ATN framework. Int J Mol Sci 24(15):12151. https:\/\/doi.org\/10.3390\/ijms241512151","journal-title":"Int J Mol Sci"},{"issue":"4","key":"7258_CR12","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-180098","volume":"63","author":"Z Cai","year":"2018","unstructured":"Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q (2018) Role of blood-brain barrier in Alzheimer\u2019s disease. J Alzheimer\u2019s disease: JAD 63(4):1223\u20131234. https:\/\/doi.org\/10.3233\/JAD-180098","journal-title":"J Alzheimer\u2019s disease: JAD"},{"issue":"7691","key":"7258_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, Fowler C, Li QX, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K (2018) High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554(7691):249\u2013254. https:\/\/doi.org\/10.1038\/nature25456","journal-title":"Nature"},{"key":"7258_CR14","doi-asserted-by":"publisher","unstructured":"Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA, Baratta M, Kolb HC, Dobler I, Mordashova Y, Saad ZS, Raunig DL, Spanakis EM, Li Y, Schindler SE, Ferber K, Rubel CE, Martone RL, Weber CJ, Edelmayer RM, Meyers EA, Bollinger JG, Rosenbaugh EG, Potter WZ; Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI); Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma A\u03b2 as a Predictor of Amyloid Positivity in Alzheimer\u2019s Disease Project Team (2022) Comparative analytical performance of multiple plasma A\u03b242 and A\u03b240 assays and their ability to predict positron emission tomography amyloid positivity. Alzheimers Dement 19(3):956\u2013966. https:\/\/doi.org\/10.1002\/alz.12697","DOI":"10.1002\/alz.12697"},{"issue":"1","key":"7258_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13195-022-01029-0","volume":"14","author":"K Yamashita","year":"2022","unstructured":"Yamashita K, Miura M, Watanabe S, Ishiki K, Arimatsu Y, Kawahira J, Kubo T, Sasaki K, Arai T, Hagino K, Irino Y, Nagai K, Verbel D, Koyama A, Dhadda S, Niiro H, Iwanaga S, Sato T, Yoshida T, Iwata A (2022) Fully automated and highly specific plasma \u03b2-amyloid immunoassays predict \u03b2-amyloid status defined by amyloid positron emission tomography with high accuracy. Alzheimers Res Ther 14(1):86. https:\/\/doi.org\/10.1186\/s13195-022-01029-0","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"7258_CR16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, Scheltens P, Teunissen CE, van der Flier WM (2018) Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 84(5):648\u2013658. https:\/\/doi.org\/10.1002\/ana.25334","journal-title":"Ann Neurol"},{"issue":"6","key":"7258_CR17","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"31","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir CA, Baker D, Blennow K, Hansson O (2016) Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep 31(6):26801. https:\/\/doi.org\/10.1038\/srep26801","journal-title":"Sci Rep"},{"issue":"1","key":"7258_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14283\/jpad.2021.70","volume":"9","author":"C Udeh-Momoh","year":"2022","unstructured":"Udeh-Momoh C, Zheng B, Sandebring-Matton A, Novak G, Kivipelto M, J\u00f6nsson L, Middleton L (2022) Blood derived amyloid biomarkers for Alzheimer\u2019s disease prevention. J Prev Alzheimers Dis 9(1):12\u201321. https:\/\/doi.org\/10.14283\/jpad.2021.70","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"7258_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","volume":"14","author":"AL Brand","year":"2022","unstructured":"Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, Lopez S, Ovod V, Nakamura A, Shaw LM, Zetterberg H, Hansson O, Bateman RJ (2022) The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimers Res Ther 14(1):195. https:\/\/doi.org\/10.1186\/s13195-022-01117-1","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"7258_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12035-019-01698-3","volume":"57","author":"Z Alirezaei","year":"2020","unstructured":"Alirezaei Z, Pourhanifeh MH, Borran S, Nejati M, Mirzaei H, Hamblin MR (2020) Neurofilament light chain as a biomarker, and correlation with magnetic resonance imaging in diagnosis of CNS-related disorders. Mol Neurobiol 57(1):469\u2013491. https:\/\/doi.org\/10.1007\/s12035-019-01698-3","journal-title":"Mol Neurobiol"},{"issue":"3","key":"7258_CR21","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/brain\/awy347","volume":"142","author":"JC Park","year":"2019","unstructured":"Park JC, Han SH, Yi D, Byun MS, Lee JH, Jang S, Ko K, Jeon SY, Lee YS, Kim YK, Lee DY, Mook-Jung I (2019) Plasma tau\/amyloid-\u03b21-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer\u2019s disease. Brain 142(3):771\u2013786. https:\/\/doi.org\/10.1093\/brain\/awy347","journal-title":"Brain"},{"issue":"8","key":"7258_CR22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, Airey DC, Knopman DS, Roberts RO, Machulda MM, Jack CR Jr, Petersen RC, Dage JL (2018) Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimer\u2019s & Dementia 14(8):989\u2013997. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.013","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"4","key":"7258_CR23","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3233\/JAD-170810","volume":"61","author":"CC Yang","year":"2018","unstructured":"Yang CC, Chiu MJ, Chen TF, Chang HL, Liu BH, Yang SY (2018) Assay of plasma phosphorylated tau protein (Threonine 181) and total tau protein in early-stage Alzheimer\u2019s disease. J Alzheimer\u2019s Dis: JAD 61(4):1323\u20131332. https:\/\/doi.org\/10.3233\/JAD-170810","journal-title":"J Alzheimer\u2019s Dis: JAD"},{"issue":"1","key":"7258_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","volume":"12","author":"H Tatebe","year":"2017","unstructured":"Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M, Kondo M, Allsop D, Tokuda T (2017) Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer\u2019s disease and down syndrome. Mol Neurodegener 12(1):63. https:\/\/doi.org\/10.1186\/s13024-017-0206-8","journal-title":"Mol Neurodegener"},{"issue":"14","key":"7258_CR25","doi-asserted-by":"publisher","first-page":"11732","DOI":"10.3390\/ijms241411732","volume":"24","author":"A Antonioni","year":"2023","unstructured":"Antonioni A, Raho EM, Lopriore P, Pace AP, Latino RR, Assogna M, Mancuso M, Gragnaniello D, Granieri E, Pugliatti M, Di Lorenzo F, Koch G (2023) Frontotemporal dementia, where do we stand? A narrative review. Int J Mol Sci 24(14):11732. https:\/\/doi.org\/10.3390\/ijms241411732","journal-title":"Int J Mol Sci"},{"issue":"2\u20133","key":"7258_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bbadis.2004.08.009","volume":"1739","author":"I D\u2019Souza","year":"2005","unstructured":"D\u2019Souza I, Schellenberg GD (2005) Regulation of tau isoform expression and dementia. Biochim Biophys Acta 1739(2\u20133):104\u2013115. https:\/\/doi.org\/10.1016\/j.bbadis.2004.08.009","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"7258_CR27","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/molecules27041210","volume":"27","author":"C Ma","year":"2022","unstructured":"Ma C, Hong F, Yang S (2022) Amyloidosis in Alzheimer\u2019s disease: pathogeny, etiology, and related therapeutic directions. Molecules 27(4):1210. https:\/\/doi.org\/10.3390\/molecules27041210","journal-title":"Molecules"},{"issue":"4","key":"7258_CR28","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.2353\/ajpath.2010.100346","volume":"177","author":"DE Hurtado","year":"2010","unstructured":"Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM (2010) A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 177(4):1977\u20131988. https:\/\/doi.org\/10.2353\/ajpath.2010.100346","journal-title":"Am J Pathol"},{"issue":"4","key":"7258_CR29","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1096\/fj.201902230RR","volume":"34","author":"H Wu","year":"2020","unstructured":"Wu H, Wei S, Huang Y, Chen L, Wang Y, Wu X, Zhang Z, Pei Y, Wang D (2020) A\u03b2 monomer induces phosphorylation of Tau at Ser-214 through \u03b22AR-PKA-JNK signaling pathway. FASEB J 34(4):5092\u20135105. https:\/\/doi.org\/10.1096\/fj.201902230RR","journal-title":"FASEB J"},{"key":"7258_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.brainresbull.2022.10.006","volume":"190","author":"DR Thal","year":"2022","unstructured":"Thal DR, Tom\u00e9 SO (2022) The central role of tau in Alzheimer\u2019s disease: from neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull 190:204\u2013217. https:\/\/doi.org\/10.1016\/j.brainresbull.2022.10.006","journal-title":"Brain Res Bull"},{"issue":"5","key":"7258_CR31","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1212\/WNL.0000000000201479","volume":"100","author":"V Planche","year":"2023","unstructured":"Planche V, Bouteloup V, Pellegrin I, Mangin JF, Dubois B, Ousset PJ, Pasquier F, Blanc F, Paquet C, Hanon O, Bennys K, Ceccaldi M, Annweiler C, Krolak-Salmon P, Godefroy O, Wallon D, Sauvee M, Boutoleau-Bretonni\u00e8re C, Bourdel-Marchasson I, Jalenques I, Chene G, Dufouil C, MEMENTO Study Group (2023) Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort. Neurology 100(5):e473\u2013e484. https:\/\/doi.org\/10.1212\/WNL.0000000000201479","journal-title":"Neurology"},{"issue":"3","key":"7258_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez J, Karikari TK, Su\u00e1rez-Calvet M, Troakes C, King A, Emersic A, Aarsland D, Hye A, Zetterberg H, Blennow K, Ashton NJ (2020) Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol 140(3):267\u2013278. https:\/\/doi.org\/10.1007\/s00401-020-02195-x","journal-title":"Acta Neuropathol"},{"issue":"3","key":"7258_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14(3):133\u2013150. https:\/\/doi.org\/10.1038\/nrneurol.2017.188","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"7258_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00018-015-2050-8","volume":"73","author":"MM Almutairi","year":"2016","unstructured":"Almutairi MM, Gong C, Xu YG, Chang Y, Shi H (2016) Factors controlling permeability of the blood-brain barrier. Cell Mol Life Sci 73(1):57\u201377. https:\/\/doi.org\/10.1007\/s00018-015-2050-8","journal-title":"Cell Mol Life Sci"},{"key":"7258_CR35","doi-asserted-by":"publisher","first-page":"271678X23118003","DOI":"10.1177\/0271678X231180035","volume":"7","author":"Y Moon","year":"2023","unstructured":"Moon Y, Jeon HJ, Han SH, Min-Young N, Kim HJ, Kwon KJ, Moon WJ, Kim SH (2023) Blood-brain barrier breakdown is linked to tau pathology and neuronal injury in a differential manner according to amyloid deposition. J Cereb Blood Flow Metab 7:271678X231180035. https:\/\/doi.org\/10.1177\/0271678X231180035","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"7258_CR36","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1208\/s12248-017-0079-3","volume":"19","author":"EM Rhea","year":"2017","unstructured":"Rhea EM, Salameh TS, Logsdon AF, Hanson AJ, Erickson MA, Banks WA (2017) Blood-Brain Barriers in Obesity. AAPS J 19(4):921\u2013930. https:\/\/doi.org\/10.1208\/s12248-017-0079-3","journal-title":"AAPS J"},{"issue":"1","key":"7258_CR37","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1038\/s41598-022-08387-7","volume":"12","author":"L Hernandez","year":"2022","unstructured":"Hernandez L, Ward LJ, Arefin S, Ebert T, Laucyte-Cibulskiene A, GOING-FWD Collaborators, Heimb\u00fcrger O, Barany P, Wennberg L, Stenvinkel P, Kublickiene K (2022) Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins. Sci Rep. 12(1):4414. https:\/\/doi.org\/10.1038\/s41598-022-08387-7","journal-title":"Sci Rep."},{"issue":"4","key":"7258_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1053\/j.ackd.2010.03.010","volume":"17","author":"LA Stevens","year":"2010","unstructured":"Stevens LA, Viswanathan G, Weiner DE (2010) Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance. Adv Chronic Kidney Dis 17(4):293\u2013301. https:\/\/doi.org\/10.1053\/j.ackd.2010.03.010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"7258_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1076-7460.2002.00998.x","volume":"11","author":"PW Wilson","year":"2002","unstructured":"Wilson PW, Kannel WB (2002) Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol. 11(2):119\u201323,125. https:\/\/doi.org\/10.1111\/j.1076-7460.2002.00998.x","journal-title":"Am J Geriatr Cardiol."},{"issue":"11","key":"7258_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fnagi.2019.00231","volume":"30","author":"R Gargini","year":"2019","unstructured":"Gargini R, Segura-Collar B, S\u00e1nchez-G\u00f3mez P (2019) Novel functions of the neurodegenerative-related gene tau in cancer. Front Aging Neurosci 30(11):231. https:\/\/doi.org\/10.3389\/fnagi.2019.00231","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"7258_CR41","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ, Puig-Pijoan A, Mil\u00e0-Alom\u00e0 M, Fern\u00e1ndez-Lebrero A, Garc\u00eda-Escobar G, Gonz\u00e1lez-Ortiz F, Kac PR, Brum WS, Benedet AL, Lantero-Rodriguez J, Day TA, Vanbrabant J, Stoops E, Vanmechelen E, Triana-Baltzer G, Moughadam S, Kolb H, Ortiz-Romero P, Karikari TK, Minguillon C, Hern\u00e1ndez S\u00e1nchez JJ, Navalpotro-G\u00f3mez I, Grau-Rivera O, Mar\u00eda Manero R, Puente-Periz V, de la Torre R, Roquer J, Dage JL, Zetterberg H, Blennow K, Su\u00e1rez-Calvet M (2023) Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement 19(5):1913\u20131924. https:\/\/doi.org\/10.1002\/alz.12841","journal-title":"Alzheimers Dement"},{"issue":"4","key":"7258_CR42","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y, Dolado AO, Triana-Baltzer G, Pontecorvo MJ, Zetterberg H, Kolb H, Vandijck M, Blennow K, Bateman RJ, Hansson O (2023) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146(4):1592\u20131601. https:\/\/doi.org\/10.1093\/brain\/awac333","journal-title":"Brain"},{"issue":"4","key":"7258_CR43","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, Blennow K, Stomrud E, Mattsson-Carlgren N, Hansson O (2023) Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement 19(4):1403\u20131414. https:\/\/doi.org\/10.1002\/alz.12787","journal-title":"Alzheimers Dement"},{"issue":"1","key":"7258_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13195-022-01011-w","volume":"14","author":"PR Kac","year":"2022","unstructured":"Kac PR, Gonzalez-Ortiz F, Simr\u00e9n J, Dewit N, Vanmechelen E, Zetterberg H, Blennow K, Ashton NJ, Karikari TK (2022) Diagnostic value of serum versus plasma phospho-tau for Alzheimer\u2019s disease. Alzheimers Res Ther 14(1):65. https:\/\/doi.org\/10.1186\/s13195-022-01011-w","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"7258_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","volume":"144","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, Su\u00e1rez-Calvet M, Zetterberg H, Blennow K, Sch\u00f6ll M, Alzheimer\u2019s Disease Neuroimaging Initiative, (2021) Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum. Brain 144(1):325\u2013339. https:\/\/doi.org\/10.1093\/brain\/awaa399","journal-title":"Brain"},{"issue":"1","key":"7258_CR46","doi-asserted-by":"publisher","first-page":"e12375","DOI":"10.1002\/dad2.12375","volume":"14","author":"CJ Fowler","year":"2022","unstructured":"Fowler CJ, Stoops E, Rainey-Smith SR, Vanmechelen E, Vanbrabant J, Dewit N, Mauroo K, Maruff P, Rowe CC, Fripp J, Li QX, Bourgeat P, Collins SJ, Martins RN, Masters CL, Doecke JD (2022) Plasma pTau181\/A\u03b21-42 ratio predicts A\u03b2-PET status and correlates with CSF-pTau181\/A\u03b21-42 and future cognitive decline. Alzheimers Dement (Amst) 14(1):e12375. https:\/\/doi.org\/10.1002\/dad2.12375","journal-title":"Alzheimers Dement (Amst)"},{"issue":"8","key":"7258_CR47","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jalz.2019.05.002","volume":"15","author":"L Jia","year":"2019","unstructured":"Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J, Zhou C, Liang F, Shi S, Wang S, Qin W, Wang Q, Li F, Wang Q, Li Y, Shen L, Wei Y, Jia J (2019) Concordance between the assessment of A\u03b242, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement 15(8):1071\u20131080. https:\/\/doi.org\/10.1016\/j.jalz.2019.05.002","journal-title":"Alzheimers Dement"},{"key":"7258_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12700","author":"F Gao","year":"2022","unstructured":"Gao F, Lv X, Dai L, Wang Q, Wang P, Cheng Z, Xie Q, Ni M, Wu Y, Chai X, Wang W, Li H, Yu F, Cao Y, Tang F, Pan B, Wang G, Deng K, Wang S, Tang Q, Shi J, Shen Y (2022) A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer\u2019s dementia: China Aging and Neurodegenerative Initiative (CANDI) study. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12700","journal-title":"Alzheimers Dement"},{"key":"7258_CR49","doi-asserted-by":"publisher","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, Spina S, Allen IE, Cobigo Y, Heuer H, VandeVrede L, Proctor NK, Lago AL, Baker S, Sivasankaran R, Kieloch A, Kinhikar A, Yu L, Valentin MA, Jeromin A, Zetterberg H, Hansson O, Mattsson-Carlgren N, Graham D, Blennow K, Kramer JH, Grinberg LT, Seeley WW, Rosen H, Boeve BF, Miller BL, Teunissen CE, Rabinovici GD, Rojas JC, Dage JL, Boxer AL, Advancing Research and Treatment for Frontotemporal Lobar Degeneration investigators (2021) Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 20(9):739\u2013752. https:\/\/doi.org\/10.1016\/S1474-4422(21)00214-3","DOI":"10.1016\/S1474-4422(21)00214-3"},{"issue":"8","key":"7258_CR50","doi-asserted-by":"publisher","first-page":"e14398","DOI":"10.15252\/emmm.202114398","volume":"13","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, Stomrud E, Zetterberg H, Alzheimer's Disease Neuroimaging Initiative, Scheltens P, Dage JL, Bouwman F, Blennow K, Mattsson-Carlgren N, Janelidze S, Hansson O (2021) Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma pTau biomarkers. EMBO Mol Med 13(8):e14398. https:\/\/doi.org\/10.15252\/emmm.202114398","journal-title":"EMBO Mol Med"},{"issue":"11","key":"7258_CR51","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ (2020) Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med 217(11):e20200861. https:\/\/doi.org\/10.1084\/jem.20200861","journal-title":"J Exp Med"},{"issue":"12","key":"7258_CR52","doi-asserted-by":"publisher","first-page":"e11170","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, Eichenlaub U, Dage JL, Chai X, Blennow K, Mattsson N, Hansson O (2019) Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med 11(12):e11170. https:\/\/doi.org\/10.15252\/emmm.201911170","journal-title":"EMBO Mol Med"},{"issue":"5","key":"7258_CR53","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Sch\u00f6ll M, Massarweh G, Soucy JP, H\u00f6glund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stomrud E, Zetterberg H, Hansson O, Rosa-Neto P, Blennow K (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19(5):422\u2013433. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5","journal-title":"Lancet Neurol"},{"issue":"1","key":"7258_CR54","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41398-021-01476-7","volume":"11","author":"SD Chen","year":"2021","unstructured":"Chen SD, Huang YY, Shen XN, Guo Y, Tan L, Dong Q, Yu JT, Alzheimer\u2019s Disease Neuroimaging Initiative (2021) Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer\u2019s disease. Transl Psychiatry 11(1):356. https:\/\/doi.org\/10.1038\/s41398-021-01476-7","journal-title":"Transl Psychiatry"},{"issue":"6","key":"7258_CR55","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/jnnp-2022-330619","volume":"94","author":"D Altomare","year":"2023","unstructured":"Altomare D, Stampacchia S, Ribaldi F, Tomczyk S, Chevalier C, Poulain G, Asadi S, Bancila B, Marizzoni M, Martins M, Lathuiliere A, Scheffler M, Ashton NJ, Zetterberg H, Blennow K, Kern I, Frias M, Garibotto V, Frisoni GB (2023) Plasma biomarkers for Alzheimer\u2019s disease: a field-test in a memory clinic. J Neurol Neurosurg Psychiatry 94(6):420\u2013427. https:\/\/doi.org\/10.1136\/jnnp-2022-330619","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"7258_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13195-023-01174-0","volume":"15","author":"Y Guo","year":"2023","unstructured":"Guo Y, Shen XN, Wang HF, Chen SD, Zhang YR, Chen SF, Cui M, Cheng W, Dong Q, Ma T, Yu JT (2023) The dynamics of plasma biomarkers across the Alzheimer\u2019s continuum. Alzheimers Res Ther 15(1):31. https:\/\/doi.org\/10.1186\/s13195-023-01174-0","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"7258_CR57","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist S, Stomrud E, Cullen N, Janelidze S, Manuilova E, Jethwa A, Bittner T, Eichenlaub U, Suridjan I, Kollmorgen G, Riepe M, von Arnim CAF, Tumani H, Hager K, Heidenreich F, Mattsson-Carlgren N, Zetterberg H, Blennow K, Hansson O (2023) An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimers Dement 19(4):1204\u20131215. https:\/\/doi.org\/10.1002\/alz.12751","journal-title":"Alzheimers Dement"},{"key":"7258_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13026","author":"J Therriault","year":"2023","unstructured":"Therriault J, Servaes S, Tissot C, Rahmouni N, Ashton NJ, Benedet AL, Karikari TK, Macedo AC, Lussier FZ, Stevenson J, Wang YT, Fernandez-Arias J, Stevenson A, Socualaya KQ, Haeger A, Nazneen T, Aumont \u00c9, Hosseini A, Rej S, Vitali P, Triana-Baltzer G, Kolb HC, Soucy JP, Pascoal TA, Gauthier S, Zetterberg H, Blennow K, Rosa-Neto P (2023) Equivalence of plasma pTau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13026","journal-title":"Alzheimers Dement"},{"issue":"12","key":"7258_CR59","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Su\u00e1rez-Calvet","year":"2020","unstructured":"Su\u00e1rez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodr\u00edguez J, Mil\u00e0-Alom\u00e0 M, Gispert JD, Salvad\u00f3 G, Minguillon C, Fauria K, Shekari M, Grau-Rivera O, Arenaza-Urquijo EM, Sala-Vila A, S\u00e1nchez-Benavides G, Gonz\u00e1lez-de-Ech\u00e1varri JM, Kollmorgen G, Stoops E, Vanmechelen E, Zetterberg H, Blennow K, Molinuevo JL, ALFA Study (2020) Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol Med 12(12):e12921. https:\/\/doi.org\/10.15252\/emmm.202012921","journal-title":"EMBO Mol Med"},{"issue":"1","key":"7258_CR60","doi-asserted-by":"publisher","first-page":"e12358","DOI":"10.1002\/dad2.12358","volume":"14","author":"P Thanapornsangsuth","year":"2022","unstructured":"Thanapornsangsuth P, Ongphichetmetha T, Luechaipanit W, Hemachudha P, Hemachudha T (2022) Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction. Alzheimers Dement (Amst) 14(1):e12358. https:\/\/doi.org\/10.1002\/dad2.12358","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"7258_CR61","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-022-01116-2","volume":"14","author":"EN Wilson","year":"2022","unstructured":"Wilson EN, Young CB, Ramos Benitez J, Swarovski MS, Feinstein I, Vandijck M, Le Guen Y, Kasireddy NM, Shahid M, Corso NK, Wang Q, Kennedy G, Trelle AN, Lind B, Channappa D, Belnap M, Ramirez V, Skylar-Scott I, Younes K, Yutsis MV, Le Bastard N, Quinn JF, van Dyck CH, Nairn A, Fredericks CA, Tian L, Kerchner GA, Montine TJ, Sha SJ, Davidzon G, Henderson VW, Longo FM, Greicius MD, Wagner AD, Wyss-Coray T, Poston KL, Mormino EC, Andreasson KI (2022) Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer\u2019s disease. Alzheimers Res Ther 14(1):172. https:\/\/doi.org\/10.1186\/s13195-022-01116-2","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"7258_CR62","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp-2022-330709","volume":"94","author":"V Vacchiano","year":"2023","unstructured":"Vacchiano V, Mastrangelo A, Zenesini C, Baiardi S, Avoni P, Polischi B, Capellari S, Salvi F, Liguori R, Parchi P, BoReALS group (2023) Elevated plasma pTau181 levels unrelated to Alzheimer\u2019s disease pathology in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 94(6):428\u2013435. https:\/\/doi.org\/10.1136\/jnnp-2022-330709","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7258_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13014","author":"B Bellaver","year":"2023","unstructured":"Bellaver B, Puig-Pijoan A, Ferrari-Souza JP, Leffa DT, Lussier FZ, Ferreira PCL, Tissot C, Povala G, Therriault J, Benedet AL, Ashton NJ, Servaes S, Chamoun M, Stevenson J, Rahmouni N, Vermeiren M, Macedo AC, Fern\u00e1ndez-Lebrero A, Garc\u00eda-Escobar G, Navalpotro-G\u00f3mez I, Lopez O, Tudorascu DL, Cohen A, Villemagne VL, Klunk WE, Gauthier S, Zimmer ER, Karikari TK, Blennow K, Zetterberg H, Su\u00e1rez-Calvet M, Rosa-Neto P, Pascoal TA (2023) Blood-brain barrier integrity impacts the use of plasma amyloid-\u03b2 as a proxy of brain amyloid-\u03b2 pathology. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13014","journal-title":"Alzheimers Dement"},{"issue":"1","key":"7258_CR64","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-022-01005-8","volume":"14","author":"C Groot","year":"2022","unstructured":"Groot C, Cicognola C, Bali D, Triana-Baltzer G, Dage JL, Pontecorvo MJ, Kolb HC, Ossenkoppele R, Janelidze S, Hansson O (2022) Diagnostic and prognostic performance to detect Alzheimer\u2019s disease and clinical progression of a novel assay for plasma pTau217. Alzheimers Res Ther 14(1):67. https:\/\/doi.org\/10.1186\/s13195-022-01005-8. (Erratum.In:AlzheimersResTher.2022Jun13;14(1):82)","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"7258_CR65","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/bios12100879","volume":"12","author":"A Shiravandi","year":"2022","unstructured":"Shiravandi A, Yari F, Tofigh N, Kazemi Ashtiani M, Shahpasand K, Ghanian MH, Shekari F, Faridbod F (2022) Earlier detection of Alzheimer\u2019s disease based on a novel biomarker cis PTau by a label-free electrochemical immunosensor. Biosensors (Basel) 12(10):879. https:\/\/doi.org\/10.3390\/bios12100879","journal-title":"Biosensors (Basel)"},{"key":"7258_CR66","doi-asserted-by":"publisher","first-page":"103837","DOI":"10.1016\/j.ebiom.2022.103837","volume":"76","author":"C Tissot","year":"2022","unstructured":"Tissot C, Therriault J, Kunach PL, Benedet A, Pascoal TA, Ashton NJ, Karikari TK, Servaes S, Lussier FZ, Chamoun M, Tudorascu DL, Stevenson J, Rahmouni N, Poltronetti NM, Pallen V, Bezgin G, Kang MS, Mathotaarachchi SS, Wang YT, Fernandez Arias J, Ferreira PCL, Ferrari-Souza JP, Vanmechelen E, Blennow K, Zetterberg H, Gauthier S, Rosa-Neto P (2022) Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine 76:103837. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103837","journal-title":"EBioMedicine"},{"key":"7258_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13083","author":"Y Cai","year":"2023","unstructured":"Cai Y, Fan X, Zhao L, Liu W, Luo Y, Lau AYL, Au LWC, Shi L, Lam BYK, Ko H, Mok VCT (2023) Comparing machine learning-derived MRI-based and blood-based neurodegeneration biomarkers in predicting syndromal conversion in early AD. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13083","journal-title":"Alzheimers Dement"},{"issue":"15","key":"7258_CR68","doi-asserted-by":"publisher","first-page":"1119070","DOI":"10.3389\/fnagi.2023.1119070","volume":"31","author":"L Shang","year":"2023","unstructured":"Shang L, Dong L, Huang X, Wang T, Mao C, Li J, Wang J, Liu C, Gao J (2023) Association of APOE \u03b54\/\u03b54 with fluid biomarkers in patients from the PUMCH dementia cohort. Front Aging Neurosci 31(15):1119070. https:\/\/doi.org\/10.3389\/fnagi.2023.1119070","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"7258_CR69","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1002\/alz.12570","volume":"18","author":"A Moscoso","year":"2022","unstructured":"Moscoso A, Karikari TK, Grothe MJ, Ashton NJ, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Sch\u00f6ll M (2022) CSF biomarkers and plasma pTau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimers Dement 18(12):2614\u20132626. https:\/\/doi.org\/10.1002\/alz.12570","journal-title":"Alzheimers Dement"},{"issue":"8","key":"7258_CR70","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1002\/alz.12997","volume":"19","author":"ZB Wang","year":"2023","unstructured":"Wang ZB, Tan L, Wang HF, Chen SD, Fu Y, Gao PY, Ma YH, Guo Y, Hou JH, Zhang DD, Yu JT, Alzheimer\u2019s disease neuroimaging initiative, (2023) Differences between ante mortem Alzheimer\u2019s disease biomarkers in predicting neuropathology at autopsy. Alzheimers Dement 19(8):3613\u20133624. https:\/\/doi.org\/10.1002\/alz.12997","journal-title":"Alzheimers Dement"},{"issue":"12","key":"7258_CR71","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/jnnp-2020-325537","volume":"92","author":"BS Rauchmann","year":"2021","unstructured":"Rauchmann BS, Schneider-Axmann T, Perneczky R, Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) (2021) Associations of longitudinal plasma pTau181 and NfL with tau-PET, A\u03b2-PET and cognition. J Neurol Neurosurg Psychiatry 92(12):1289\u20131295. https:\/\/doi.org\/10.1136\/jnnp-2020-325537","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"7258_CR72","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Su\u00e1rez-Calvet M, Saha-Chaudhuri P, Lussier F, Kvartsberg H, Rial AM, Pascoal TA, Andreasson U, Sch\u00f6ll M, Weiner MW, Rosa-Neto P, Trojanowski JQ, Shaw LM, Blennow K, Zetterberg H, Alzheimer\u2019s Disease Neuroimaging Initiative (2021) Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol Psychiatry 26(2):429\u2013442. https:\/\/doi.org\/10.1038\/s41380-020-00923-z","journal-title":"Mol Psychiatry"},{"issue":"8","key":"7258_CR73","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1750-1326-8-38","volume":"22","author":"F Marques","year":"2013","unstructured":"Marques F, Sousa JC, Sousa N, Palha JA (2013) Blood-brain-barriers in aging and in Alzheimer\u2019s disease. Mol Neurodegener 22(8):38. https:\/\/doi.org\/10.1186\/1750-1326-8-38","journal-title":"Mol Neurodegener"},{"issue":"12","key":"7258_CR74","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/cns.12476","volume":"21","author":"A Martorana","year":"2015","unstructured":"Martorana A, Di Lorenzo F, Belli L, Sancesario G, Toniolo S, Sallustio F, Sancesario GM, Koch G (2015) Cerebrospinal fluid A\u03b242 levels: when physiological become pathological state. CNS Neurosci Ther 21(12):921\u2013925. https:\/\/doi.org\/10.1111\/cns.12476","journal-title":"CNS Neurosci Ther"},{"key":"7258_CR75","doi-asserted-by":"publisher","first-page":"105755","DOI":"10.1016\/j.nbd.2022.105755","volume":"170","author":"Q Zeng","year":"2022","unstructured":"Zeng Q, Li K, Luo X, Wang S, Xu X, Jiaerken Y, Liu X, Hong L, Hong H, Li Z, Fu Y, Zhang T, Chen Y, Liu Z, Huang P, Zhang M, for behalf of Alzheimer's Disease Neuroimaging Initiative (ADNI) (2022) The association of enlarged perivascular space with microglia-related inflammation and Alzheimer's pathology in cognitively normal elderly. Neurobiol Dis 170:105755. https:\/\/doi.org\/10.1016\/j.nbd.2022.105755","journal-title":"Neurobiol Dis"},{"issue":"7","key":"7258_CR76","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, Bu G, Vemuri P, Graff-Radford J, Jack CR Jr, Petersen RC (2022) Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med 28(7):1398\u20131405. https:\/\/doi.org\/10.1038\/s41591-022-01822-2","journal-title":"Nat Med"},{"issue":"16","key":"7258_CR77","doi-asserted-by":"publisher","first-page":"980658","DOI":"10.3389\/fnins.2022.980658","volume":"19","author":"X Wang","year":"2023","unstructured":"Wang X, Chen X, Tang Y, Zhang L, Wang Y, Hou Z, Jang W, Yuan Y (2023) The impact of hemodiafiltration on cognitive function in patients with end-stage renal disease. Front Neurosci 19(16):980658. https:\/\/doi.org\/10.3389\/fnins.2022.980658","journal-title":"Front Neurosci"},{"issue":"2","key":"7258_CR78","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.26134","volume":"90","author":"Z Lin","year":"2021","unstructured":"Lin Z, Sur S, Liu P, Li Y, Jiang D, Hou X, Darrow J, Pillai JJ, Yasar S, Rosenberg P, Albert M, Moghekar A, Lu H (2021) Blood-brain barrier breakdown in relationship to Alzheimer and vascular disease. Ann Neurol 90(2):227\u2013238. https:\/\/doi.org\/10.1002\/ana.26134","journal-title":"Ann Neurol"},{"issue":"1","key":"7258_CR79","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/alz.12000","volume":"16","author":"J Kaplow","year":"2020","unstructured":"Kaplow J, Vandijck M, Gray J, Kanekiyo M, Huyck E, Traynham CJ, Esquivel R, Fagan AM, Luthman J (2020) Concordance of Lumipulse cerebrospinal fluid t-tau\/A\u03b242 ratio with amyloid PET status. Alzheimers Dement 16(1):144\u2013152. https:\/\/doi.org\/10.1002\/alz.12000","journal-title":"Alzheimers Dement"},{"key":"7258_CR80","doi-asserted-by":"publisher","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","volume":"76","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS, Mathotaarachchi S, Therriault J, Savard M, Chamoun M, Stoops E, Francois C, Vanmechelen E, Gauthier S, Zimmer ER, Zetterberg H, Blennow K, Rosa-Neto P (2022) Cerebrospinal fluid pTau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. EBioMedicine 76:103836. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103836","journal-title":"EBioMedicine"},{"issue":"10","key":"7258_CR81","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/alz.12545","volume":"18","author":"C Delaby","year":"2022","unstructured":"Delaby C, Teunissen CE, Blennow K, Alcolea D, Arisi I, Amar EB, Beaume A, Bedel A, Bellomo G, Bigot-Corbel E, Bjerke M, Blanc-Quintin MC, Boada M, Bousiges O, Chapman MD, DeMarco ML, D\u2019Onofrio M, Dumurgier J, Dufour-Rainfray D, Engelborghs S, Esselmann H, Fogli A, Gabelle A, Galloni E, Gondolf C, Grandhomme F, Grau-Rivera O, Hart M, Ikeuchi T, Jeromin A, Kasuga K, Keshavan A, Khalil M, K\u00f6rtvelyessy P, Kulczynska-Przybik A, Laplanche JL, Lewczuk P, Li QX, Lle\u00f3 A, Malaplate C, Marqui\u00e9 M, Masters CL, Mroczko B, Nogueira L, Orellana A, Otto M, Oudart JB, Paquet C, Paoletti FP, Parnetti L, Perret-Liaudet A, Peoc\u2019h K, Poesen K, Puig-Pijoan A, Quadrio I, Quillard-Muraine M, Rucheton B, Schraen S, Schott JM, Shaw LM, Su\u00e1rez-Calvet M, Tsolaki M, Tumani H, Udeh-Momoh CT, Vaudran L, Verbeek MM, Verde F, Vermunt L, Vogelgsang J, Wiltfang J, Zetterberg H, Lehmann S (2022) Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer\u2019s disease: an international overview. Alzheimers Dement 18(10):1868\u20131879. https:\/\/doi.org\/10.1002\/alz.12545","journal-title":"Alzheimers Dement"},{"issue":"1","key":"7258_CR82","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3233\/JAD-210677","volume":"85","author":"NR Barth\u00e9lemy","year":"2022","unstructured":"Barth\u00e9lemy NR, Toth B, Manser PT, Sanabria-Boh\u00f3rquez S, Teng E, Keeley M, Bateman RJ, Weimer RM, Wildsmith KR (2022) Site-specific cerebrospinal fluid tau hyperphosphorylation in response to Alzheimer\u2019s disease brain pathology: not all tau phospho-sites are hyperphosphorylated. J Alzheimers Dis 85(1):415\u2013429. https:\/\/doi.org\/10.3233\/JAD-210677","journal-title":"J Alzheimers Dis"},{"key":"7258_CR83","doi-asserted-by":"publisher","unstructured":"Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, Mollenhauer B, Pilotto A, Lemstra A, Paquet C, Abdelnour C, Kramberger MG, Bonanni L, Vandenberghe R, Hye A, Blennow K, Zetterberg H, Aarsland D, European\u2013Dementia With Lewy Bodies (E-DLB) Consortium (2022) Association of plasma pTau181 and pTau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies. JAMA Neurol 79(1):32\u201337. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4222","DOI":"10.1001\/jamaneurol.2021.4222"},{"issue":"3","key":"7258_CR84","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41380-019-0437-x","volume":"26","author":"HIL Jacobs","year":"2021","unstructured":"Jacobs HIL, Riphagen JM, Ramakers IHGB, Verhey FRJ (2021) Alzheimer\u2019s disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms. Mol Psychiatry 26(3):897\u2013906. https:\/\/doi.org\/10.1038\/s41380-019-0437-x","journal-title":"Mol Psychiatry"},{"issue":"1","key":"7258_CR85","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-170602","volume":"62","author":"BM Bettcher","year":"2018","unstructured":"Bettcher BM, Johnson SC, Fitch R, Casaletto KB, Heffernan KS, Asthana S, Zetterberg H, Blennow K, Carlsson CM, Neuhaus J, Bendlin BB, Kramer JH (2018) Cerebrospinal fluid and plasma levels of inflammation differentially relate to CNS markers of Alzheimer\u2019s disease pathology and neuronal damage. J Alzheimers Dis 62(1):385\u2013397. https:\/\/doi.org\/10.3233\/JAD-170602","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"7258_CR86","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3390\/biomedicines10102667","volume":"10","author":"M Arcaro","year":"2022","unstructured":"Arcaro M, Fenoglio C, Serpente M, Arighi A, Fumagalli GG, Sacchi L, Floro S, D\u2019Anca M, Sorrentino F, Visconte C, Perego A, Scarpini E, Galimberti D (2022) A novel automated chemiluminescence method for detecting cerebrospinal fluid amyloid-beta 1\u201342 and 1\u201340, total tau and phosphorylated-tau: implications for improving diagnostic performance in Alzheimer\u2019s disease. Biomedicines 10(10):2667. https:\/\/doi.org\/10.3390\/biomedicines10102667","journal-title":"Biomedicines"},{"issue":"1","key":"7258_CR87","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","volume":"18","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK (2023) Plasma phospho-tau in Alzheimer\u2019s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegener 18(1):18. https:\/\/doi.org\/10.1186\/s13024-023-00605-8","journal-title":"Mol Neurodegener"},{"issue":"1","key":"7258_CR88","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M (2022) Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol 21(1):66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6","journal-title":"Lancet Neurol"},{"issue":"5","key":"7258_CR89","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, Snellman A, Sch\u00f6ll M, Troakes C, Hye A, Gauthier S, Vanmechelen E, Zetterberg H, Rosa-Neto P, Blennow K (2021) Plasma pTau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol 141(5):709\u2013724. https:\/\/doi.org\/10.1007\/s00401-021-02275-6","journal-title":"Acta Neuropathol"},{"issue":"1","key":"7258_CR90","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, Ashton NJ, Zetterberg H, Blennow K, Vanbrabant J, Stoops E, Vanmechelen E, Dage JL, Teunissen CE (2021) Clinical and analytical comparison of six Simoa assays for plasma PTau isoforms PTau181, PTau217, and PTau231. Alzheimers Res Ther 13(1):198. https:\/\/doi.org\/10.1186\/s13195-021-00939-9","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"7258_CR91","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simr\u00e9n","year":"2021","unstructured":"Simr\u00e9n J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-Carlgren N, Sch\u00f6ll M, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Lovestone S, Aarsland D, AddNeuroMed consortium, Hansson O, Rosa-Neto P, Westman E, Blennow K, Zetterberg H, Ashton NJ (2021) The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement 17(7):1145\u20131156. https:\/\/doi.org\/10.1002\/alz.12283","journal-title":"Alzheimers Dement"},{"issue":"8","key":"7258_CR92","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A, Mattsson-Carlgren N, Strandberg O, Smith R, Villegas A, Sepulveda-Falla D, Chai X, Proctor NK, Beach TG, Blennow K, Dage JL, Reiman EM, Hansson O (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324(8):772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134","journal-title":"JAMA"},{"issue":"9","key":"7258_CR93","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, Salvad\u00f3 G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, Gonz\u00e1lez-Escalante A, S\u00e1nchez-Benavides G, Minguillon C, Fauria K, Molinuevo JL, Dage JL, Zetterberg H, Gispert JD, Su\u00e1rez-Calvet M, Blennow K (2022) Plasma pTau231 and pTau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med 28(9):1797\u20131801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w","journal-title":"Nat Med"},{"issue":"3","key":"7258_CR94","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM, Morris JC, Karch CM, Xiong C, Allegri R, Mendez PC, Berman SB, Ikeuchi T, Mori H, Shimada H, Shoji M, Suzuki K, Noble J, Farlow M, Chhatwal J, Graff-Radford NR, Salloway S, Schofield PR, Masters CL, Martins RN, O\u2019Connor A, Fox NC, Levin J, Jucker M, Gabelle A, Lehmann S, Sato C, Bateman RJ, McDade E, Dominantly Inherited Alzheimer Network (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med 26(3):398\u2013407. https:\/\/doi.org\/10.1038\/s41591-020-0781-z","journal-title":"Nat Med"},{"issue":"Pt 4","key":"7258_CR95","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist S, Mattsson N, Hansson O, Alzheimer\u2019s Disease Neuroimaging Initiative (2016) Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography. Brain 139(Pt 4):1226\u201336. https:\/\/doi.org\/10.1093\/brain\/aww015","journal-title":"Brain"},{"issue":"4","key":"7258_CR96","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaneurol.2019.4749","volume":"77","author":"PF Meyer","year":"2020","unstructured":"Meyer PF, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S (2020) Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography. JAMA Neurol 77(4):508\u2013516. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4749. (Erratum in: JAMA Neurol. 2020 Feb 17;: Erratum in: JAMA Neurol. 2021 Mar 1;78(3):370)","journal-title":"JAMA Neurol"},{"issue":"2","key":"7258_CR97","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3390\/biom13020290","volume":"13","author":"Z Mohammadi","year":"2023","unstructured":"Mohammadi Z, Alizadeh H, Marton J, Cumming P (2023) The sensitivity of tau tracers for the discrimination of Alzheimer\u2019s disease patients and healthy controls by PET. Biomolecules 13(2):290. https:\/\/doi.org\/10.3390\/biom13020290","journal-title":"Biomolecules"},{"issue":"8","key":"7258_CR98","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A (2019) Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry 24(8):1112\u20131134. https:\/\/doi.org\/10.1038\/s41380-018-0342-8","journal-title":"Mol Psychiatry"},{"issue":"5","key":"7258_CR99","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/acn3.51529","volume":"9","author":"AM Brickman","year":"2022","unstructured":"Brickman AM, Manly JJ, Honig LS, Sanchez D, Reyes-Dumeyer D, Lantigua RA, Vonsattel JP, Teich AF, Kang MS, Dage JL, Mayeux R (2022) Correlation of plasma and neuroimaging biomarkers in Alzheimer\u2019s disease. Ann Clin Transl Neurol 9(5):756\u2013761. https:\/\/doi.org\/10.1002\/acn3.51529","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"7258_CR100","doi-asserted-by":"publisher","first-page":"e15098","DOI":"10.15252\/emmm.202115098","volume":"13","author":"J Lantero-Rodriguez","year":"2021","unstructured":"Lantero-Rodriguez J, Snellman A, Benedet AL, Mil\u00e0-Alom\u00e0 M, Camporesi E, Montoliu-Gaya L, Ashton NJ, Vrillon A, Karikari TK, Gispert JD, Salvad\u00f3 G, Shekari M, Toomey CE, Lashley TL, Zetterberg H, Su\u00e1rez-Calvet M, Brinkmalm G, Rosa Neto P, Blennow K (2021) PTau235: a novel biomarker for staging preclinical Alzheimer\u2019s disease. EMBO Mol Med. 13(12):e15098. https:\/\/doi.org\/10.15252\/emmm.202115098","journal-title":"EMBO Mol Med."}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07258-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07258-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07258-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T23:40:44Z","timestamp":1715298044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07258-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["7258"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07258-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"3 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}